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Abstract
A number of biological agents are available or being investigated for the treatment of asthma and
rhinitis. The safety profiles of these biologic agents, which may modify allergic and immunological
diseases, are still being elucidated. Subcutaneous allergen immunotherapy, the oldest biologic agent
in current use, has the highest of frequency of the most serious and life-threatening reaction,
anaphylaxis. It is also one of the only disease modifying interventions for allergic rhinitis and asthma.
Efforts to seek safer and more effective allergen immunotherapy treatment have led to
investigations of alternate routes of delivery and modified immunotherapy formulations. Sublingual
immunotherapy appears to be associated with a lower, but not zero, risk of anaphylaxis. No
fatalities have been reported to date with sublingual immunotherapy. Immunotherapy with
modified formulations containing Th1 adjuvants, DNA sequences containing a CpG motif (CpG)
and 3-deacylated monophospholipid A, appears to provide the benefits of subcutaneous
immunotherapy with a single course of 4 to 6 preseasonal injections. There were no serious
treatment-related adverse events or anaphylaxis in the clinical trials of these two immunotherapy
adjuvants. Omalizumab, a monoclonal antibody against IgE, has been associated with a small risk of
anaphylaxis, affecting 0.09% to 0.2% of patients. It may also be associated with a higher risk of
geohelminth infection in patients at high risk for parasitic infections but it does not appear to affect
the response to treatment or severity of the infection.
Clinical trials with other biologic agents that have targeted IL-4/IL-13, or IL-5, have not
demonstrated any definite serious treatment-related adverse events. However, these clinical trials
were generally done in small populations of asthma patients, which may be too small for uncommon
side effects to be identified. There is conflicting information about the safety TNF-alpha blocking
agents, which have been primarily used in the treatment of rheumatoid arthritis, with serious
infections, cardiovascular disease and malignancies being the most frequent serious adverse events.
An unfavorable risk-benefit profile led to early discontinuation of a TNF-blocking agent in a double-
blind placebo controlled of severe asthmatics.
In summary, the risk of anaphylaxis and other treatment-related serious events with of all of the
biological agents in this review were relatively small. However, most of the clinical trials were done
in relatively small patient populations and were of relatively short duration. Long term studies in
large patient populations may help clarify the risk-benefit profile of these biologic agents in the
treatment of asthma.
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Introduction
A number of therapeutic agents are available to treat the
symptoms and inflammation associated with allergic
rhinitis and asthma. Despite the proven efficacy of these
medications, there continues to be some patients whose
asthma [1] or rhinitis [2] is not well controlled. In addi-
tion, medications currently available for allergic rhinitis
and asthma treatment appear to be are only effective while
taken and do not appear to provide a sustained benefit
after discontinuation [3]. Limitations of current medica-
tions and a greater understanding of the pathogenesis of
allergic disease, has lead to the development of number of
a novel therapeutic approaches as well as renewed interest
in an old therapeutic approach, specific allergen immuno-
therapy. Novel therapeutic approaches that have been
used in the treatment of allergic rhinitis and asthma
include: omalizumab, alternate immunotherapy routes
such as sublingual, modified allergen immunotherapy
vaccines, anti-interleukin 5 (mepolizumab), interleukin-4
variant (pitrakinra) and tumor necrosis factor (TNF-α)
blocking agents. The intent of this paper is to review the
safety of these novel therapeutic approaches (see table 1
for summary of biological agents reviewed). Although the
focus of the review is safety, there will be some discussion
of the efficacy of these biological agents.
Definition and incidence of anaphylaxis
One of the difficulties in evaluating the safety of biologics
is that some of the suspected adverse events may be
related to the disease itself. For example, an increased risk
of malignancy has been reported with TNF-alpha block-
ers, which are used primarily in the treatment of rheuma-
toid arthritis (RA). A systematic review and meta-analysis
of 9 clinical trials that included 3493 RA patients treated
with the anti-TNF-alpha antibodies, inflxumab or adali-
mumab, found a dose-related increase in malignancies
Table 1: Summary of biological agents used in the treatment of asthma and allergic rhinitis
Biological agent Disease studied Target Mechanisms Safety Efficacy
SCIT AR & asthma Specific 
aeroallergens or 
venom
Several immune changes 
including↑IL-10 & TGF-β. 
isotype switch to IgG
Surveys suggest; fatality 
rate of 1 in 2.5 million 
injections34-36 & near fatal 
reaction rate of 5.4 per 1 
million injections37
Appears to depend on 
dose
SLIT AR & asthma Specific 
aeroallergens
Probably similar to SCIT Most common AEs oral-
mucosal symptoms
AE less common than SCIT 
but cases of anaphylaxis 
have been reported
A consistent relationship 
with dose and  efficacy 
has not been 
established39
MPL AR TRL4 Shift toward Th1 
response
SRs reported in 1.6% of the 
1736 patients in 
postmarking surveillence 
survey50
Clinical efficacy seen in 
first treat season after 4 
injection treatment 
course
CpG AR TRL9 Shift toward Th1 
response
No serious treatment-
related effects46
Clinical efficacy seen in 
1st & 2nd treatment 
season after one 4 
injection course46
Omalizumab Asthma & AR IgE Prevents binding of IgE to 
mast cells and basophils, 
downregulatuion of IgE 
receptor on these cells
Anaphylaxis in 0.09 to 0.2% 
of patients19,20
Efficacy in medication 
reduction & 
exacerbation in asthma, 
clinical improvement in 
AR
Mepolizumab Asthma IL-5 Blocks binding of IL-5 to 
α receptor on 
eosinophils
One episode of 
hypotension after infusion 
in EE study57
No significant 
improvement in 
asthma55
Pintrakinra58 Asthma IL-4Rα receptor Competes with IL-4 and 
IL-13 for binding to the 
receptor
Non-neutralizing IgG anti- 
pintrakinra antibodies in 
~30% of pts
Increased PD20 
inmethacholine challenge 
& asthma AE & beta-
agonist use
Etanercept Asthma TNF-alpha soluble TNF-alpha 
receptor
No significant treatment-
related AE is asthma 59 but 
increased risk of serious & 
opportunistic infection in 
rheumatologic disease
Increased markers of 
TNF-alpha activity & 
improved clinical 
outcomes in refractory 
asthma 59
SCIT = subcutaneous immunotherapu, SLIT = sublingual immunotherapy, AR = allergic rhinitis, MPL = -deacylated monophospholipid A, CpG = 
immunostimulatory oligonucleotide sequence of DNA containing a CpG motif, TNF-alpha = tumor necrosis factor alpha, AE = adverse event, SAE 
= serious adverse event, EE = eosinophilic esophagitis, PD20 = Provocative Dose, which produces a decrease in FEV1 by 20% from the initial value 
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compared with the control groups with a pooled odds
ratio of 3.3 (95% confidence interval [CI], 1.2-9.1) [4].
This increased rate of malignancy was not seen in another
study that compared the incidence of malignancy and car-
diovascular disease in two large RA observational data-
bases: BIOBADSER, a registry for safety of biologics,
which included 4459 RA patients on TNF-alpha blocking
agents in 100 centers who were followed from 2001 to
2006 and EMECAR, an external RA cohort (n = 789) estab-
lished to define the characteristics of the disease and to
assess comorbidity [5]. In the EMECAR registry, during
the period of 1999 to 2005, a TNF-alpha blocking agent
was given to 1.4%, 10.6% and 16.8% of the patients in
2000, 2003 and 2005, respectively. A higher incidence of
malignancies was found in the EMECAR database
patients, which included a minority receiving TNF-alpha
blocking agents, compared with the BIOBADSER registry,
in which all received a TNF-alpha blocking agents there
was a higher incidence of malignancy in EMECAR vs.
BIOBADSER (Relative Risk (RR) 2.9) and a lower BIOBA-
DASER by EMECAR cancer-related mortality ratio, 0.36
(0.10-1.30).
Likewise, atopy and asthma have been identified as risk
factors for anaphylaxis, the most severe and potentially
life-threatening reaction associated with the biologics dis-
cussed in this review [6]. The incidence of anaphylaxis
appears to be greater in the asthmatic population and this
may be dependent on the severity of asthma. A review of
a large patient database in the United Kingdom was per-
formed to determine the incidence of anaphylaxis in the
asthmatic and general population [7]. Specific Read codes
were used to identify potential cases of anaphylaxis. All
patients (10-79 years), who had at least one year of enroll-
ment with a general practitioner and one health contact in
the previous year during the period of 1996-2005 were
included. Two cohorts were identified: asthmatic patients
(791,225 person-yrs of follow-up) and the general popu-
lation (884,745 person-years of follow-up). Within the
asthmatic cohort, a subset of severe asthmatics, were iden-
tified based on meeting any of the following 4 criteria: '
1. ≥ 1 asthma hospitalization
2. ≥ 12 canisters of inhaled beta--agonists a year
3. ≥ 3 prescriptions of oral corticosteroids a year,
4. ≥ 3 classes of asthma medication a year
There were a total of 224 cases of anaphylaxis: 170 in the
asthma population and 54 in the general population. The
anaphylaxis incidence rate (cases/100,000 person-years)
was highest in the severe asthmatic group: 43.1 in severe
asthma patients, 15.4 in non-severe asthma patients and
6.1 in the general population. Compared to the general
population, the age-gender adjusted RR for anaphylaxis
was greater in both the severe asthmatic patients (RR 7.2,
95% confidence interval (CI), 5.0--10.3) and non-severe
asthmatic patients (RR 2.5, 95% CI, 1.8--3.5). The authors
concluded that there may be an increased risk of anaphy-
laxis in asthmatic patients that may be dependent on the
severity of asthma.
Another variable and difficulty in interpreting the safety of
biologics in research and postmarketing surveillance is
that there is no universal agreement on the definition of
anaphylaxis or the criteria for its diagnosis. In an attempt
to resolve this problem, the National Institute of Allergy
and Infectious Disease and Food Allergy and Anaphylaxis
Network convened a meeting, which included representa-
tives from multiple organizations and 3 continents, with
the intent of developing a universally accepted definition
of anaphylaxis and establishing clinical criteria that would
accurately identify cases of anaphylaxis [8]. The working
group developed three sets of criteria for the diagnosis of
anaphylaxis (table 2). These criteria are used in some of
the studies reviewed in this paper. However, in many
studies and reviews, particularly ones involving allergen
immunotherapy, the criteria for diagnosing anaphylaxis is
not clear. Recognizing that adverse reactions to biological
agents may be distinctly different from side-effects from
chemicals and drugs, a classification system for adverse
reactions to these agents has been proposed (table 3) [9].
This classification distinguishes five different categories:
Type α reactions due to high cytokine levels, type β reac-
tions due to a hypersensitivity reaction against the biolog-
ical agent, type γ reactions due to immune or cytokine
imbalance syndromes, type δ reactions due to cross-reac-
tivity between the biological agent's target and cells that
express similar or identical antigens and type ε reactions,
which do not directly affect the immune system.
Omalizumab
One of the most studied biologics for the treatment of
asthma and rhinitis is omalizumab. Omalizumab is a
95% humanized monoclonal antibody (mAb) that binds
to the Fc portion of the circulating immunoglobulin E
(IgE) molecule preventing it from attaching to the high
affinity IgE receptor, FcεR1. Omalizumab produces signif-
icant and rapid reductions in free serum IgE (up to 99%)
[10]. One study demonstrated a 96% reduction in mean
serum IgE level three days after omalizumab administra-
tion [11]. With continued treatment there is subsequent
downregulation of the FcεR1 expression on several cell
types that occurs over the next 4 to 6 months [12,13].
Omalizumab has been shown to be effective in the treat-
ment of allergic asthma and seasonal and perennial rhin-
itis [14-17]. It is currently approved by the United StatesAllergy, Asthma & Clinical Immunology 2009, 5:4 http://www.aacijournal.com/content/5/1/4
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(US) Food and Drug Administration (FDA) for the treat-
ment of moderate-to-severe persistent allergic asthma in
adults and children 12 years and older. Omalizumab is
also suggested as a treatment consideration for allergic
asthmatics who are not well controlled with the combina-
tion of a medium-dose inhaled corticosteroid and a long-
acting beta-agonist in the recently published expert panel
guidelines on diagnosis and management of asthma [18].
These guidelines note that omalizumab is the only adju-
vant therapy to demonstrate added efficacy to the com-
bined regimen of a high-dose inhaled corticosteroid and a
long-acting beta agonist [19].
The most common adverse reaction from omalizumab is
injection- site pain and bruising but the package insert
contains warnings regarding malignancies, geohelmith
infections and a "black box" warning about anaphylaxis.
A "black box warning is the highest level of 5 possible
warning categories found in pharmaceutical package
inserts [20]. It is recommended, in the informed consent
process, that patients be specifically informed that a med-
ication has a "black box" warning and the reason for the
"black box" warning be provided [20]. The "black box"
warning on anaphylaxis (type β effect) was recently added
Table 2: Clinical criteria for diagnosing anaphylaxis8
Anaphylaxis is highly likely when any one of the following 3 
criteria are fulfilled:
1. Acute onset of an illness (minutes to several hours) with involvement 
of the skin, mucosal tissue, or both 
(e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula)
AND AT LEAST ONE OF THE FOLLOWING a. Respiratory compromise 
(e.g., dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)
b. Reduced BP or associated symptoms of end-organ dysfunction 
(e.g., hypotonia [collapse], syncope, incontinence)
2. Two or more of the following that occur rapidly after 
exposure to a likely allergen for that patient (minutes to 
several hours):
a. Involvement of the skin-mucosal tissue 
(e.g., generalized hives, itch-flush, swollen lips-tongue-uvula)
b. Respiratory compromise 
(e.g., dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)
c. Reduced BP or associated symptoms 
(e.g., hypotonia [collapse], syncope, incontinence)
d. Persistent gastrointestinal symptoms 
(e.g., crampy abdominal pain, vomiting)
3. Reduced BP after exposure to known allergen for that 
patient (minutes to several hours):
a. Infants and children: low systolic BP (age specific) or greater than 30% 
decrease in systolic BP*
b. Adults: systolic BP of less than 90 mm Hg or greater than 30% 
decrease from that person's baseline
PEF = Peak expiratory flow; BP = blood pressure.
*Low systolic blood pressure for children is defined as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg 1 [2 times age]) from 1 to 
10 years, and less than 90 mm Hg from 11 to 17 years.
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et al. Second symposium on the definition and management of 
anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J 
Allergy Clin Immunol, 2006:391-7.
Table 3: Proposed classification of adverse side effects of biological agents9
Classification Mechanism (s) Clinical features
Type α High cytokine & cytokine release syndrome Symptoms will depend on the cytokine or cytokine being targeted e.g., high levels of 
INF-α may cause 'flu-like symptoms and anti- CD3 (muromunab) may induce 
cytokine release syndrome, which may include the following symptoms: flushing, 
arthralgias, capillary leak syndrome with pulmonary edema, encephalopathy, and 
severe gastrointestinal symptoms
Type β Hypersensitivity Immediate (IgE)
Delayed (IgG or T cell)
Type γ Immune or cytokine imbalance syndrome Autoimmunity
Allergic/atopic disorders
Impaired function (immunodeficiency)
Type δ Cross-reactivity Will depend on the function of the cross-reacting antigen; e.g., Acneiform eruptions 
are commonly seen with cetuximab, an anti- epidermal growth factor receptor 
(EGFR) mAb possibly due to cross-reactivity between skin ERFR.
Type ε Non-immunologic side-effects Varies with the function of the biological agent; Interferon-α frequently associated 
with neuropsychiatric adverse effectsAllergy, Asthma & Clinical Immunology 2009, 5:4 http://www.aacijournal.com/content/5/1/4
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to Xolair® (omalizumab) package insert at the direction of
the FDA in response to the spontaneous postmarketing
adverse event-reports. A review of spontaneous postmar-
keting adverse events submitted to the FDA and Genen-
tech/Novartis suggested that at least 0.2% of patients who
received Xolair® (omalizumab) experienced anaphylaxis
between June 2003 and December 2006 [21]. The review
also noted that many of the cases were delayed in onset
and characterized by a protracted progression. An Omali-
zumab Joint Task Force of the American Academy of
Allergy, Asthma and Immunology and the American Col-
lege of Allergy, Asthma and Immunology (OJTF) also
reviewed the postmarketing surveillance data from the
same time period [22]. Using the definition of anaphy-
laxis proposed at a 2005 multidisciplinary symposia [8],
the OJTF concluded that 35 patients had 41 episodes of
anaphylaxis associated with omalizumab administration.
During this time period 39,510 patients received omalizu-
mab, thus the anaphylaxis-reporting rate was 0.09% of
patients. Of those 36 events, for which the time of reac-
tion was known, 22 (61%) reactions occurred in the first
2 hours after one of the first 3 doses and within 30 min-
utes in 5 (14%) of the events that occurred after the fourth
or later doses.
The OJTF report recommends an observation period of 2
hours for the first 3 injections and 30 minutes for subse-
quent injections because 75% of the anaphylactic reac-
tions occurred within these time periods. The OJTF report
also provided recommendations on patient education
regarding anaphylaxis.
Omalizumab and malignancies
In the initial Xolair® (omalizumab) clinical trials, a higher
incidence of malignancies was observed in the group that
received Xolair® (omalizumab): 20/4127 (0.5%) Xolair®
(omalizumab)-treated patients compared with 5/2236
(0.2%) patients in the control group [23]. The observed
malignancies in the Xolair®  (omalizumab)--treated
patients were heterogeneous in tumor type and organ.
There were no new cases of lymphoproliferative disease
and no cases were considered drug-related by a panel of
blinded independent oncologists. The majority of cases
(60%) were diagnosed within 6 months of treatment [24].
Overall, the clinical data did not suggest a causal relation-
ship between Xolair®  (omalizumab) and malignancy.
However, the Xolair® (omalizumab) package insert does
note that "the impact of longer exposure to Xolair or use
in patients at higher risk for malignancy (e.g., elderly, cur-
rent smokers) is not known" [24]. A multicenter, prospec-
tive, observational cohort study titled Evaluating the
Clinical Effectiveness and Long-Term Safety in Patients
with Moderate to Severe Asthma (EXCELS) that includes
approximately 5000 Xolair® (omalizumab) -treated and
2500 with moderate to severe asthma not receiving
Xolair® (omalizumab), designed to evaluate the long term
safety of Xolair® (omalizumab) is currently in progress
[25].
Cardiovascular and Cerebrovascular disease
On July 16, 2009, the FDA issued a statement indicating
that review of the EXCELS study's interim safety data
showed an excess of cardiovascular and cerebrovascular
events in the patients on Xolair® (omalizumab) compared
with the asthma control group [26]. The interim data sub-
mitted by the manufacturer, Genentech, suggests a dispro-
portionate increase in ischemic heart disease,
arrhythmias, cardiomyopathy and cardiac failure, pulmo-
nary hypertension, cerebrovascular disorders, and
embolic, thrombotic and thrombophlebitic events in
patients treated with on Xolair® (omalizumab) compared
with the group that did not receive this medication.
Being an observational study, many factors need to be
evaluated before determining the relationship between
Xolair® (omalizumab) and these adverse events. Consider-
ing that Xolair® (omalizumab) is indicated for moderate-
to-severe asthma and the prescribing/administration
process can involve a fair amount of physician and staff
time, as well as, patient time and expense, it is likely there
were considerable differences between the Xolair® (omali-
zumab)-treated group and the asthma control group in
terms of asthma severity and co-morbidities. These differ-
ences may include oral corticosteroid use, underlying car-
diovascular disease or hypertension and may account for
the differences in adverse events. The FDA did not recom-
mend any changes to the prescribing information (i.e.,
package insert) on Xolair® (omalizumab) but did recom-
mend that patients and physicians be aware that the new
information from the EXCELS study may suggest a risk of
crdiovascular and cerebrovascular events.
Omalizumab and geohelminth infection
Considering that IgE may have a protective role in the
immunity against parasitic infections, there are concerns
that anti-IgE antibodies might impair this protective effect
and increase susceptibility to parasite infection (type γ
effect). The Xolair® (omalizumab) package insert recom-
mends that patients at high risk for geohelminth infec-
tions be monitored for such infections while on treatment
citing a 1-year study of patients at high-risk for geo-
helminth infections, in which the odds ratio for infection
in the Xolair® (omalizumab)-treated group was1.96 with a
95% CI (0.88-4.36) compared with the placebo control.
Similar results were seen in a 1-year double-blind, pla-
cebo-controlled (DBPC) trial of 137 subjects (12-30
years) at high risk of geohelminth infection, who were
randomized to receive 52 weeks of treatment with Xolair®
(omalizumab) or placebo [27]. After adjusting for base-
line infection status, gender, age and study visit, there wasAllergy, Asthma & Clinical Immunology 2009, 5:4 http://www.aacijournal.com/content/5/1/4
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a significant difference in the incidence of intestinal geo-
helminth infection between the 2 groups (adjusted OR
2.2 95% CI; 0.94-5.15, p = 0.035:) However, there was no
increased morbidity in terms of laboratory or clinical
adverse events in the Xolair®  (omalizumab)-treated
patients compared with the placebo group. The response
to anti-geohelminth treatment was no different from the
placebo group in both studies. These studies suggest that
individuals at high-risk for geohelminth infections may
be a greater risk for infection during Xolair® (omalizu-
mab) treatment but the infection severity and response to
treatment is similar to placebo-treated patients.
Allergen immunotherapy
Although this form of therapy is nearly 100 years old, it
remains one of the only disease-modifying treatments for
allergic asthma and rhinitis [28-30]. Subcutaneous immu-
notherapy (SCIT) with unmodified allergen extracts is cur-
rently the most widely used modality worldwide.
However, sublingual immunotherapy (SLIT) has been
prescribed with increasing frequency in the past 25 years,
particularly in certain parts of Europe. SCIT efficacy
appears to be dose dependent and the immunological
mechanisms responsible for the clinical efficacy of immu-
notherapy are still being elucidated. Immunological
changes associated with SCIT include induction of T regu-
latory cells, increase in allergen-specific IgG4, increase in
IL-10 and TGF-β production and down-regulation of the
TH-2 response [31]. Allergen immunotherapy has, been
shown to decrease the recruitment of mast cells, basophils
and eosinophils in the skin, nose, eye and bronchial
mucosa, following provocation or natural exposure to
allergens blocking both the immediate and late-phase
allergic response [32]. Adverse reactions from SCIT
include common local injection site reactions to rare life-
threatening anaphylaxis and death. The frequency of sys-
temic reactions with SCIT appears to be related to the
schedule and dose. In one review of 38 SCIT studies the
systemic reaction (SR) rate with conventional build-up
schedules (single dose increase per visit) ranged between
0.05% to 3.2% of injections and 0.8% to 46.7% of
patients (mean,12.92%) [33]. In a 1-year prospective
study of a multi-physician practice, there were 98 SRs in
96/4578 (2%) patients [34]. There was a significant differ-
ence in per injection SR rate between the maintenance (1
per 1831 visits) and build-up phase (1 per 1063 visits, p =
0.01).
Accelerated immunotherapy build-up schedules for inha-
lant allergens may be associated with greater risk,
although this has not been consistently demonstrated
with cluster schedules (2 to 3 injections per visit on non-
consecutive days). A recent review of accelerated immuno-
therapy schedules found the SR rate for rush immuno-
therapy (multiple injections given over 1 to 3 days)
ranged from 15% to 100% of patients without premedica-
tion and 14.7% to 38% of patients with premedication
[35]. A similar range was seen with cluster schedules,
although one study specifically designed to compare the
safety of a cluster schedule with a conventional schedule
found no significant difference in the SR rate between the
groups and the clinical and objective parameters
improved 6 weeks sooner in the cluster group [36].
Severe reactions from SCIT are relatively rare but fatal
reactions (FR) have been reported at a rate of 1 in 2 to 2.5
million injections or an average of 3.4 deaths per year in
surveys of AAAAI membership that span the time period
from 1945 to 2001 [37-39]. Symptomatic or poorly con-
trolled asthma has been identified as a risk factor for a FR
from SCIT. The most recent survey also assessed the fre-
quency of SCIT near-fatal reactions (NFR) defined as
severe respiratory compromise and/or fall in blood pres-
sure requiring emergency treatment with epinephrine
[40]. The incidence of unconfirmed NFRs was 23 per year
or 5.4 events per one million injections. Important con-
tributing factors for NFR included administration during
peak of the allergy season (46% of respondents) and dos-
ing errors (25% of respondents) Fifty-eight percent of the
NFR received injections from the maintenance concen-
trate.
Sublingual immunotherapy
One of the purported advantages of SLIT over SCIT is
greater safety. Like SCIT, the mechanisms of SLIT are still
being elucidated but studies have suggested similar
immunological changes with SLIT [41]. A number of stud-
ies have demonstrated the efficacy of SLIT in the treatment
of allergic rhinitis and asthma, but the determinants of
SLIT efficacy have not been clearly established. There did
not appear to be a consistent relationship between dose
and SLIT efficacy in a comprehensive review of 104 arti-
cles on SLIT [42]. In this review, there were 66 studies that
provided some information on SLIT safety. In these 66
studies, there were approximately 1,181,000 doses given
to 4378 patients. There were no fatalities or events
described as anaphylaxis, although there were 14 proba-
ble serious adverse events (7 were asthma reactions).
Oral-mucosal reactions, considered a SLIT local reaction,
were relatively common, affecting up to 75% of patients,
and seen most frequently in the build-up phase. In the
studies that specified the type of reaction, 169 of 314,959
(0.056% of doses administered) were classified as SRs
There were 244 moderate adverse events (AE) requiring
dose adjustment or causing withdrawal from the study in
2939 patients treated for 4586 treatment years with
810,693 doses of SLIT (50 studies). The majority of these
reactions were gastrointestinal symptoms, rhinoconjunc-
tivitis, urticaria or some combination of these symptoms.
There were no identified risk factors for SLIT adverse reac-Allergy, Asthma & Clinical Immunology 2009, 5:4 http://www.aacijournal.com/content/5/1/4
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tions in this review. There did not appear to be a consist-
ent relationship between adverse reactions and SLIT dose
or induction schedule and the majority of studies were
done in rhinitis/rhinoconjunctivitis patient with or with-
out mild-to-moderate asthma. There were no studies in
high risk patients (e.g., moderate to severe asthmatics).
Subsequent to this review, there have been several case
reports of SLIT-associated anaphylaxis:
￿ One occurred on the 3rd day of build-up with a
multi-allergen SLIT [43]
￿ One occurred on maintenance at the height of sea-
son [44]
￿ One occurred on the 4th day of a latex rush protocol
[45].
￿ One occurred after a 3 week gap in maintenance
treatment after taking a dose 6 times higher than pre-
scribed. This reaction resulted in loss of consciousness
and admission to the intensive care unit [46].
Four cases of SRs with SLIT have been reported in individ-
uals who had to discontinue SCIT due to a SR [47,48].
Two cases occurred after the first dose of a grass tablet
[48]. The other two cases occurred with the maintenance
dose of SLIT administered as drops shortly after complet-
ing an ultrarush protcocol [47].
Some of the factors in the above cases are risk factors that
have been identified with SCIT: height of season, history
of prior SRs, dose and schedule. Further studies are
needed to identify and characterize SLIT risk factors.
Modified allergen vaccines and adjuvants
Efforts to develop safer and more effective allergen immu-
notherapy vaccines have resulted in several modifications
to the allergen extracts. Allergoids are modified allergen
extracts that have been processed in a way that reduces the
extract's allergenicity while preserving its immunogenic-
ity. Adjuvants have also been used to enhance the effec-
tiveness of allergen immunotherapy primarily by shifting
the immune response toward Th1 production. The two
adjuvants that have been most extensively studied in the
treatment of allergic rhinitis, are an immunostimulatory
oligonucleotide sequence of DNA containing a CpG motif
(CpG) and 3-deacylated monophospholipid A (MPL),
both of which target toll-like receptors (TLR). Toll-like
receptors play a key role in activating antigen-presenting
cells and when stimulated can influence the Th1/Th2
cytokine balance. The receptor for CpG DNA is TLR9,
which is primarily expressed on plamacytoid dendritic
cells [49]. Activation can lead production of IL-10, IgG
isotype switching and other inhibition of other immune
responses mediated by Th2 cells. TOLAMBA, a TLR9 ago-
nist, is a CpG adjuvant that is covalently linked to the
major ragweed allergen Amb a 1. A randomized DBPC,
phase 2 trial of 25 adults with ragweed-induced allergic
rhinitis randomized to receive 6 increasing doses of
TOLAMBA (0.06, 0.3,1.2, 3.0, 6.0 and 12 mcg) or placebo
before the ragweed season and followed through 2 rag-
weed seasons found no "pattern of vaccine-associated sys-
temic reactions or clinically significant laboratory
abnormalities" [50]. Although, there was no difference in
the primary outcome, which was albumin level in nasal-
lavage fluid after nasal allergen provocation, there was a
significant reduction in total nasal symptom scores during
the peak season in the TOLAMBA group compared with
the placebo-treated patients in both the first and second
ragweed season. A subsequent placebo-controlled trial of
738 subjects with ragweed-induced allergic rhinitis who
were randomized to either a high dose regimen
(TOLAMBA 3,9,30,30,30, 30 mcg), a low dose regimen
(TOLAMBA 1,2,3,6,15,21, 30 mcg) or placebo reported
that treatment "was well tolerated in all groups" and that
there were no TOLAMBA-related serious adverse events
[51]. On January 8, 2007 Dynavax Technologies Corpora-
tion announced that the analysis of interim one-year data
from this two-year study (DARTT trial) indicated that
there was "no measurable disease during the ragweed sea-
son in any of the study groups making it impossible to
measure the therapeutic effect of TOLAMBA treatment
and the study" [52]. Based on these results, Dynavax Tech-
nologies decided to discontinue development of
TOLAMBA.
MPL, the other adjuvant used in allergen immunotherapy
is derived from the lipopolysaccharide of Salmonella Min-
nesota R595. It contains lipid A, which is a TLR4 agonist,
that has been has been shown to induce TH1 cytokines in
human and animal studies. An allergen vaccine composed
of a tyrosine-absorbed (delays absorption), glutaralde-
hyde-modified allergen (allergoid) containing the MPL
adjuvant has been shown to provide significant improve-
ment in clinical and immunological parameters in
patients with seasonal rhinitis [53-55]. The dosing regi-
men was 4 doses (300,800, 2000, 2000 standardized units
(SU) administered at 1-2 week intervals ending 2 to 4
weeks before the start of season. The highest dose and
cumulative dose was equivalent to 24 mcg and 60 mcg of
group 1 grass pollen allergen, respectively [53]. The treat-
ment was well tolerated in the clinical trials with systemic
adverse events occurring at a similar frequency in the
active and placebo groups [53,56,57]. There were no seri-
ous or severe adverse events or anaphylactic reactions in
these clinical trials. In a one-year postmarketing surveil-
lance assessment of 1736 patients, who received a total of
8512 injections, systemic reactions were reported by1.6%Allergy, Asthma & Clinical Immunology 2009, 5:4 http://www.aacijournal.com/content/5/1/4
Page 8 of 11
(page number not for citation purposes)
of the patients [54]. Fourteen patients reported severe
reactions but there were no instances of anaphylactic
shock. One of the potential adverse effects of concern with
Th1-inducing adjuvants is autoimmunity (type γ effect).
In addition to the clinical immunotherapy trials, MPL has
been used as an adjuvant in licensed vaccines for many
years: Melacine® (Corixa Inc./Schering-Plough, Canada)
and the human papillomavirus, Ceravarix® (Glaxo-Smith-
Kline, UK). To date, there has been no evidence of
increased incidence of autoimmune diseases in the popu-
lations that have been exposed to MPL
In the past four years, there have been several clinical trials
designed to study the efficacy and safety of MPL in the
treatment of grass-pollen or ragweed-induced allergic
rhinitis (Grass MATAMPL, RagweedMATAMPL, Allergy
Therapeutics Ltd.) conducted in the US and Canada.
However, the FDA placed a clinical hold on all of MPL-
related vaccine studies in the US after a case of transverse
myelitis was reported in the grass-pollen study.
Mepolizumab (anti-IL-5)
Mepolizumab is a high-affinity, humanized non-comple-
ment-fixing IgG1mAb that blocks binding of IL-5 to the α
chain receptor complex on eosinophils. IL-5 plays key role
in eosinophilic differentiation, maturation, migration,
activation and survival and it is highly expressed in bron-
chial alveolar lavage fluid and biopsies of asthmatics. Sin-
gle dose and multiple dose (6 monthly) intravenous and
subcutaneous mepolizumab toxicity studies in monkeys
found no target organ toxicity or immunotoxicity with
doses up to 300 mg/kg [58]. In a DBPC study of 363 asth-
matics, symptomatic on inhaled corticosteroids, rand-
omized to 3 infusions of either placebo, 250 mg or 750
mg of mepolizumab, there were no significant differences
between the 3 groups in any of the clinical outcomes [59].
However there was a trend toward reduced exacerbations
in the 750 mg dose group (p = 0.065). Side effects were
similar in the three groups and there were no serious
adverse events attributed to the study medication. The
withdrawal rate due to adverse reactions was highest in
the placebo group: placebo (5%), 250 mg (3.3%) and 750
mg 0.9%). Mepolizumab has also been used is small
open-label studies of patients with eosinophilic disorders.
In a study of 4 patients with hypereosinophilic syndrome,
who received 3 infusions of up to 750 mcg of mepolizu-
mab, there was a reduction in peripheral eosinophils and
clinical improvement in all 4 patients [60]. The only
reported medication- related AEs were fatigue and head-
ache after the infusions. In another open label study of 4
patients with eosinophilic esophagitis treated with the
same protocol, there was one episode of symptomatic
hypotension 30 minutes after the 3rd  infusion, which
resolved with fluid replacement [61]. The investigators
questioned whether this was related to the infusion. Other
symptoms reported in this trial included nausea, fatigue,
headache, non-specific chest pain and cough. All patients
reported improved clinical outcomes.
Essentially, there was one possible serious-adverse event
(hypotension) and no evidence of cytokine imbalance
syndrome (type γ effect) in the relatively small popula-
tions of patients in these mepolizumab clinical trials.
Interleukin-4 and Interleukin-13 Inhibition
Interleukin-4 (IL-4) and Interleukin-13 (IL-13) are
cytokines that play a role in allergic inflammation by
inducing Th2 responses. Interleukin-4Rα is the signaling
component of the receptor complex for both IL-4 and IL-
13. Pitrakinra is a recombinant IL-4 variant that competi-
tively binds IL-4Rα receptor inhibiting the binding of
both IL-4 and IL-13. Two DBPC 28 day trials of pitrakina
administered subcutaneously (SQ) or via nebulizer dem-
onstrated some clinical efficacy [62]. There was a signifi-
cant difference in post allergen challenge FEV1 compared
with the placebo group in the SQ pitrakinra study and
fewer asthma-related adverse events and beta-agonist res-
cue use in the group that received inhaled pitrakinra.
There were also no significant differences in safety out-
comes between the pitrakinra and placebo groups except
for an increased frequency of injection site reactions in
those who received SQ pitrakinra. IgG antibodies against
pitrakinra were seen 3/10 patients in the SQ study (titers
of 1:40 and 1:80) and 3/15 patients in the inhalation
study (titers were1:30, 1:60, and 1:480). None of IgG anti-
bodies against pitrakinra were able to block the binding of
the drug to interleukin 4Rα; i.e., they were non-neutraliz-
ing antibodies.
Tumor Necrosis Factor Alpha Blocking Agents
TNF-alpha blocking agents have been used extensively in
rheumatology primarily in the treatment of rheumatoid
arthritis. One randomized DBPC, cross-over study investi-
gated the effects of ten-weeks of treatment with etaner-
cept, a soluble TNF-alpha receptor, administered twice
weekly to 10 patients with refractory asthma [63]. Etaner-
cept was associated with a significant increase in the meth-
acholine provocation dose (P = 0.05), an improvement in
the asthma-related quality of life scores (by 0.85 point; P
= 0.02), and a 0.32-liter increase in post-bronchodilator
FEV1 (p = 0.01). There were no treatment-related adverse
events or withdrawals. The study also measured markers
of TNF-alpha activity and found that patients with refrac-
tory asthma had increased expression of membrane-
bound TNF-alpha, TNF-alpha receptor 1, and TNF-alpha-
converting enzyme by peripheral-blood monocytes com-
pared with the mild-to-moderate asthma and the control
groups. This study suggests that patients with refractoryAllergy, Asthma & Clinical Immunology 2009, 5:4 http://www.aacijournal.com/content/5/1/4
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asthma may have up-regulation of the TNF-alpha axis and
may benefit from treatment with a TNF-alpha blocking
agent.
In a double-blind placebo controlled trial 309 patients
with severe, uncontrolled asthma randomized to one of 3
doses of the TNF-alpha blocking agent, golimumab
administered subcutaneously (50, 100 or 200 mg) once a
month or placebo, there was no significant difference in
clinical efficacy between the 4 groups [64]. There was a
higher frequency of severe adverse reactions, including
serious and life-threatening infections in the golimumab-
treated groups compared with placebo. One death and all
8 malignancies occurred in the golimumab-treated
groups. The steering committee decided to discontinue
the study-agent administration after reviewing the safety
data at the Week-24 database lock.
The relatively small patient populations studied in these
trials makes it difficult to assess the safety of TNF-alphas
blocking agents in asthma. However, these agents have
been extensively studied in rheumatologic diseases. In an
open-label extension study of 257 patients with ankylos-
ing spondylitis treated for up to 192 weeks with etaner-
cept, injection site reactions, diarrhea and headaches were
the most frequent complaints [65]. The rate for serious
infections, which is listed in a 'black-box' labeled warning
in the package insert, was 0.02 per patient-year. The safety
of TNF-alpha blocking agents was evaluated in an open,
prospective study of 163 patients with juvenile idiopathic
arthritis: 68 received infliximab and 95 received etaner-
cept [66]. Adverse leading to discontinuation occurred in
26 (32.1%) patients treated with Infliximab and 18
(14.2%) patients treated with etanercept. The authors
noted that some AEs, "..such as thrombocytopenia, neuro-
psychiatric disorders, new onset of Crohn's disease, new
onset or flare-up of chronic iridocyclitis, were unusual
and had rarely been described before, yet proved to be sig-
nificant in frequency and/or clinically noteworthy in the
large population.." they followed. One review of 18 rand-
omized trials involving 8800 patients, found no increase
in the odds of death, serious adverse events, serious infec-
tion, lymphoma, non-melanoma skin cancers or the com-
posite endpoint of non-cutaneous cancers plus
melanomas with recommended doses of TNF-alpha
blocking agents when evaluated using the unadjusted
meta-analytic method [67]. For individuals receiving two
to three the times the recommended dose of the TNF-
alpha blocking agent, there was a twofold increase in seri-
ous infection.
As discussed earlier in the paper there are conflicting data
on the risk of malignancies with TNF-alpha blocking
agents [4,5]. In August of 2009, the FDA notified health-
care professionals that it has completed its analysis of
TNF-alpha blocking agents and concluded that there is an
increased risk of lymphoma and other cancers associated
with the use of these drugs in children and adolescence
[68]. The current prescribing information for TNF-alpha
blocking agents does contain a warning for malignancies,
but does not specifically mention leukemia. This new
safety information is now being added to the Boxed Warn-
ing for these products.
Other potentials safety issues with TNF-alpha blocking
agents include (all type γ effects): [69-71]
￿Increased susceptibility to tuberculosis (TB) and cer-
tain opportunistic infections or reactivation of latent
TB--screening prior to initiation of therapy should
include identifying risk for latent TB (e.g., HIV infec-
tion, drug addiction, living in a region of high TB prev-
alence, etc.), tuberculin skin test and chest x-ray [70]
￿Serious bacterial infections: incidence of 0.07 to 0.09
per patient year compared 0.01 to 0.06 per control
population year [70]
￿Autoimmune- like syndromes: lupus-like reactions,
demyelinating syndromes
Conclusion
There are several reasons why biologic agents may offer
distinct advantages over conventional pharmacotherapy
in the treatment of rhinitis and asthma. Both conditions
are likely to present with active symptoms requiring some
medical management for many years [72]. Biological
agents that have an immunomodulatory effect such as
allergen immunotherapy may produce sustained clinical
improvement after discontinuation of treatment,
Whereas, conventional pharmacotherapy is generally only
effective during active treatment [3]. The most serious
adverse reaction from biologic agents is anaphylaxis and
this has been seen most frequently seen in SCIT with
unmodified extracts. The delivery of these unmodified
allergens via the sublingual route appears to be associated
with less risk of anaphylaxis and similar efficacy.
Newer immunotherapy formulations containing Th1
adjuvants (CpG and MPL) appear to provide the benefits
of SCIT with a much shorter course of treatment (4 to 6
injections) and a lower risk of adverse events. Biologic
agents that target specific components of the immune sys-
tem may provide clinical efficacy to patients that have
failed to respond to optimal pharmacotherapy. Omalizu-
mab is the most extensively studied and prescribed agent
for the treatment of allergic asthma that targets a single
molecule. Adverse reactions to omalizumab are uncom-
mon but anaphylaxis (none fatal) has been reported at a
rate of 0.09 to 0.2% of patients. Some studies have sug-Allergy, Asthma & Clinical Immunology 2009, 5:4 http://www.aacijournal.com/content/5/1/4
Page 10 of 11
(page number not for citation purposes)
gested that patients on omalizumab, who are at high risk
of geohelminth infections, may be more susceptible to
parasitic infection but not more resistant to treatment.
Other biologic agents targeting IL-5, and IL-4/IL-13 did
not demonstrate any serious or severe treatment-related
adverse events in asthma patients, There has been some
conflicting information on the safety of TNF-alpha block-
ing agents in the treatment of asthma.
In general, these biological agents were studied in clinical
trials that included relatively small patient populations
and there may have not been a sufficient number of
patients to identify adverse treatment-related events that
occur at a low frequency. Some uncommon adverse
effects, such as 1 fatality in 2.5 million SCIT injections or
anaphylaxis in 0.09% of omalizumab-treated patients,
may not become apparent in clinical trials or postmarket-
ing surveillance data until a very large number of patients
have been studied or the medication has been in use for
several years. In general, the risk of serious reactions, such
as anaphylaxis, with these biological agents is relatively
small, and may be reduced by appropriate medical super-
vision during treatment.
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